Novo Nordisk announced today that the U.S. Food and Drug Administration (FDA) approved a new indication for use of the oral antidiabetic drug (OAD) Prandin® (repaglinide): combination therapy with rosiglitazone or pioglitazone, members of another class of OADs called insulin sensitizers, for the treatment of type 2 diabetes.
Prandin, an “insulin secretagogue” because it stimulates insulin secretion, was previously approved for use as monotherapy or in combination with metformin, another type of insulin sensitizer.
The new indication for Prandin is important because combination therapy may improve control of blood glucose levels for many people with type 2 diabetes whose condition has progressed and oral monotherapy together with diet and exercise cannot maintain adequate glycemic control. At that point, combination therapy with an additional OAD with a different mechanism of action may be appropriate.
“Prandin is a highly effective agent to use with insulin sensitizers because of its ability to augment mealtime insulin secretion and proven efficacy in attaining glycemic control,” said Alan J. Garber, M.D., Ph.D., professor of medicine, biochemistry and cell biology at Baylor College of Medicine in Houston.
He explained that Prandin, which is taken with meals, in part to control postprandial glycemia, rapidly stimulates insulin secretion, whereas insulin sensitizers primarily improve the body’s response to the hormone. He said that two recent studies support this combination approach, showing that, among patients previously poorly controlled with monotherapy with either a sulfonylurea or metformin, “the combination of Prandin with a sensitizer resulted in better blood glucose control than monotherapy with either of these agents alone.”
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!